Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps Sells 61,582 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 61,582 shares of Tempus AI stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $82.36, for a total value of $5,071,893.52. Following the sale, the executive vice president now owns 153,080 shares in the company, valued at $12,607,668.80. This represents a 28.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Erik Phelps also recently made the following trade(s):

• On Wednesday, February 5th, Erik Phelps sold 5,934 shares of Tempus AI stock. The shares were sold at an average price of $67.57, for a total transaction of $400,960.38.

Tempus AI Stock Down 10.5 %

Shares of NASDAQ:TEM opened at $76.72 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The stock’s fifty day moving average price is $49.75 and its 200-day moving average price is $51.44.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC boosted its stake in shares of Tempus AI by 132.1% in the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after buying an additional 3,141,487 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its position in Tempus AI by 166.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock valued at $93,251,000 after purchasing an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Tempus AI by 86,947.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock valued at $55,836,000 after purchasing an additional 1,651,996 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. TD Cowen reissued a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.